Patient Safety Alert: Falsely Elevated Glucose Monitor Readings in Patients Receiving Icodextrin (Extraneal) Peritoneal Dialysis Solution
2012-06-12 14:14:10
Submitted by: Submitted by Sara Alexanian, MD
Glucose has been the traditional osmotic agent used in peritoneal dialysis (PD) solutions. However, osmotic agents, including a glucose polymer called icodextrin, are now available and pose a safety Read More

"Does Calcium Supplementation Increase CHD Risk?"
2012-05-30 15:15:00
Submitted by: Nelson Watts, MD
As covered in recent news reports in the lay press, Li et al (Li K, et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the Eu Read More

The Food and Drug Administration (FDA) Issues a Safety Label Change for Statin Drugs
2012-03-06 10:26:00
Submitted by: AACE
The Food and Drug Administration (FDA) issued a safety label change for statin drugs. Of principal concern to endocrinologists are the changes related to increases in blood glucose and the dosage warning related to lovastatin. Read More

“No Significant Change in Recommendations for Calcium and Vitamin D": Conclusion from an analysis of a meta-analysis.
2010-09-24 16:01:47
Submitted by: Daniel L. Hurley, MD, FACE
Mark Bolland and colleagues have recently published a meta-analysis of studies in the British Medical Journal (http://www.ncbi.nlm.nih.gov/pubmed/20671013) to investigate whether calcium supplements increase the risk of cardiovascular (CV) events. Read More

FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events
2010-06-11 14:23:43
Submitted by: Alan J. Garber, MD, PhD, FACE
AACE Liaison to the FDA and Editor, AACE Patient Safety Exchange
The U.S. Food and Drug Administration (FDA) is evaluating data from two clinical trials in which patients with type 2 diabetes taking the blood pressure medication, Benicar (olmesartan) had a higher rate of death from a cardiovascular cause compared to pat Read More

FDA Statement on Thyrogen
2010-05-26 16:59:45
Submitted by: Daniel Einhorn, MD, FACP, FACE
AACE President

Alan J. Garber, MD, PhD, FACE
AACE Liaison to the FDA and Editor, AACE Patient Safety Exchange
As a consequence of previous concerns raised regarding contamination resulting from particulate material in Thyrogen, the FDA and Genzyme have entered into a legal settlement which will limit the availability of a drug used in the treatment and diagnostic Read More

FDA MedWatch - Orlistat (marketed as Alli and Xenical): Labeling Change
2010-05-26 14:22:22
Submitted by: Food and Drug Administration (FDA) MedWatch
The FDA Safety Information and Adverse Event Reporting Program
FDA notified healthcare professionals and patients that it has approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been reported rarely with the use of this medication. Read More

FDA Drug Safety Communication: New Boxed Warning on severe liver injury with propylthiouracil
2010-05-04 08:56:36
Submitted by: Food and Drug Administration (FDA) MedWatch
The FDA Safety Information and Adverse Event Reporting Program
The United States Food and Drug Administration (FDA) has added a Boxed Warning to the label for propylthiouracil, a drug used to treat hyperthyroidism, to include information about reports of severe liver injury and acute liver failure, some of which have Read More

GnRH Agonists: Safety Review of Drug Class Used to Treat Prostate Cancer-Possible increased risk of diabetes and certain cardiovascular diseases
2010-05-04 08:51:32
Submitted by: Food and Drug Administration (FDA) MedWatch
The FDA Safety Information and Adverse Event Reporting Program
FDA notified healthcare professionals and patients of FDA's preliminary and ongoing review which suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists Read More

Response to oral bisphosphonates news reports
2010-03-11 11:44:53
Submitted by: Steven M. Petak, MD, JD, FACE, FCLM
President, American College of Endocrinology

OneTouch SureStep Test Strips: Recall-Test strips may provide falsely low results when glucose level is over 400 mg/dL
2010-03-01 13:49:39
Submitted by: Alan Garber, MD, PhD
Editor, AACE Patient Safety Exchange
LifeScan and FDA notified healthcare professionals of a voluntary recall of eight lots of OneTouch SureStep Test Strips, used by people with diabetes to measure their blood glucose levels at home. Read More

FDA Alert RE: Levemir
2009-06-15 08:52:36
Submitted by: AACE